The FDA's Enforcement Paradox: Warning Letters, Import Bans, and China Supply Chain Scrutiny as Deregulation Signals Grow

Key takeaways

• The Trump administration is reportedly crafting plans to allow temporary sale of certain previously restricted peptides while new regulations are finalised, according to sources cited by the Washington Post on 7 October 2026.
• In the same period, the FDA issued a coordinated cluster of five warning letters to online peptide sellers in August 2026, targeting products marketed with "research use only" disclaimers that the agency concluded were intended for human drug use.
• A July 2026 federal sentencing resulted in a 70-month prison term combined with a $5 million forfeiture for a peptide distributor, signalling that warning letters can escalate to criminal prosecution.
• Chinese API supplier Chengdu Shengnuo Biopharmaceutical was placed on FDA Import Alert 66-40 in September 2026 and suspended all peptide API shipments to the US market — a supply chain event relevant to procurement leads across the English-speaking research community.
• State pharmacy boards in Ohio, Washington, and Alabama have independently tightened enforcement against research-labelled peptide products used in clinical settings.

Two signals travelling in opposite directions

The peptide regulatory landscape in early October 2026 presents a pronounced contradiction. The Washington Post reported on 7 October that the Trump administration is crafting plans that would allow the temporary sale of certain previously restricted peptides as federal health officials hammer out new regulations around the controversial products. The reporting drew on two people familiar with the deliberations.

At the same time, Forbes noted on 9 October that enforcement is complicated by an international supply chain that includes overseas manufacturers and distributors, and import records show multiple shipments of retatrutide entered the US in early 2026. The agency is, in short, signalling deregulation through one channel while issuing enforcement notices through another.

For research procurement professionals, both signals matter. The deregulation trajectory affects what may eventually become compoundable under 503A rules; the enforcement trajectory affects what risks attach to current sourcing decisions.

The August 2026 warning-letter sweep

In August 2026, FDA issued warning letters to five online sellers — NuScience Peptides LLC, Royal Peptides LLC, Peptide Partners LLC, Peak Performance Peptides, and TXP Innovations LLC (d/b/a Tex Peptides) — for marketing unapproved and misbranded peptide products.

All four warning letters were dated August 24, 2026 and issued by the Office of Unapproved Drugs and Labeling Compliance within CDER, each triggered by an FDA review of the recipient's website conducted in July 2026.

The products cited were broad in scope. Individual letters cite products including semaglutide, tirzepatide, retatrutide, survodutide, mazdutide, SS-31, PT-141, tesamorelin, ipamorelin blends, and bacteriostatic water sold for reconstitution.

The "research use only" defence did not hold. Even though the companies labelled their products "for research, laboratory, and analytical use" and "not for veterinary or human use," FDA found that dosing information, injection instructions, and dose calculators posted on each company's website established that the products were intended for human use. FDA also found that several companies' "bacteriostatic water" offerings were themselves unapproved drugs, since they were intended for use in preparing an injection.

All five share the subject line "Unapproved New Drugs/Misbranded" and were issued by CDER's Office of Unapproved Drugs and Labeling Compliance. Publishing several similar letters together on the same date signals a coordinated compliance sweep focused on online peptide marketing, not an isolated dispute with one company.

Notably, the FDA warning letters did not reference any of the six peptides that FDA's Pharmacy Compounding Advisory Committee recommended for inclusion on the 503A Bulk Drugs List in July 2026. The two processes — deregulation through PCAC and enforcement through CDER — appear to be operating on separate tracks.

When a warning letter becomes a criminal matter

The August letters are formal compliance notices, not final legal determinations. However, they can be the first step in an escalating sequence. The FDA issued three waves of GLP-1 warning letters between September 2025 and June 2026: more than 50 letters in September 2025, 30 in March 2026, and 25 in June 2026.

The criminal ceiling is tangible. The FDA has escalated enforcement against online peptide sellers through warning letters and criminal prosecution, while state medical boards impose stricter standards on prescribers. Recent actions reveal how research-use-only disclaimers fail when evidence shows intended human use, and one case resulted in a 70-month prison sentence combined with $5 million forfeiture.

A separate case — the Department of Justice prosecution of Tailor Made Compounding — further illustrated the limits of regulatory protection. The Department of Justice prosecuted Tailor Made Compounding for distributing unapproved peptides, including BPC-157, to patients and providers nationwide. The company was forced to forfeit $1.79 million and entered into a consent decree that effectively ended its peptide operations. The case is particularly significant because Tailor Made operated as a compounding pharmacy, a category that typically enjoys certain regulatory protections under Section 503A and 503B of the FDCA. The prosecution made clear that compounding exemptions do not apply to peptides that the FDA has not approved for human use.

China supply chain: the Shengnuo import ban

The enforcement pressure extends well upstream of the retail seller. The single most consequential supply chain event of recent weeks involved a Chinese API manufacturer.

China's Shengnuo announced on September 22 that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical, was placed on the FDA's Import Alert 66-40 list on September 19. The company suspended all sales and shipments of peptide active pharmaceutical ingredients (APIs) to the US market until the alert is lifted.

The import alert stems from eight observations documented in a Form FDA 483 issued after an on-site inspection in August, covering critical quality attribute identification, contamination control capabilities, and quality system governance.

Shengnuo Biotech's most scrutinised business segment is GLP-1 peptide APIs, including semaglutide API and tirzepatide API, the latter of which was filed with the FDA in May this year. In the first half of 2026, the company's US sales reached 167 million yuan (approximately $24.9 million), accounting for 32.83% of total revenue.

Following the news, Shengnuo's stock fell 18.61%, with market capitalisation shrinking to 4.405 billion yuan (approximately $657 million).

The Shengnuo action sits within a broader enforcement posture towards Chinese API suppliers. As reported by Peptide Staff in May 2026, the FDA expanded its import alert programme in May 2026 to cover 38 additional foreign manufacturers of peptide APIs. The action represents the most aggressive enforcement posture the FDA has taken against overseas peptide ingredient sourcing, and Import Alert 66-40 now flags manufacturers in China, India, and South Korea responsible for an estimated 30% of the injectable peptide API supply entering the US market annually.

State-level enforcement adds another layer

Federal enforcement is being amplified at the state level. Ohio reinforced its position in December 2025 Board of Pharmacy guidance, advising that medications labelled "for research purposes only," or with similar language, are unlawful for prescriber clinics and medical spas to possess, regardless of patient consent. The guidance encourages providers to dispose of RUO products and advise patients to discontinue their use.

Ohio's pharmacy board reports summarily suspending more than thirty clinics and medical spas since the beginning of 2025. Washington's Pharmacy Quality Assurance Commission also took concrete action, imposing a stop-service order on a GLP-1 sterile compounder for sterile compounding and licensure failures.

Meanwhile, blockchain analytics firm Chainalysis estimates that grey-market peptide cryptocurrency transactions reached $32 million in the first quarter of 2026. Additionally, some peptide-selling companies have been tracked for selling fentanyl precursors, and Chinese shippers have concealed peptide orders inside packages labelled as ordinary merchandise. The co-mingling of peptide supply chains with other illicit trade is a factor that is likely to sustain law enforcement attention irrespective of the deregulatory signals coming from HHS.

What this means for research procurement

The tension between the administration's deregulatory ambitions and the FDA's active enforcement posture creates a genuinely complex operating environment. Several principles bear emphasis for UK and US laboratory procurement teams.

"Research use only" labelling is not a legal shield. A seller cannot place "not for human consumption" in the footer and then advertise a peptide as if it treats a condition. That mismatch creates enforcement risk — and, per the warning letters, extends liability to the seller rather than insulating the buyer.

Supplier due diligence must now encompass API provenance. The Shengnuo ban and the May 2026 import-alert expansion demonstrate that quality-system failures at the API manufacturer level can sever supply without warning. Procurement teams sourcing from compounders or research chemical vendors with Chinese API inputs should request documentation of Import Alert 66-40 status for their specific suppliers.

Deregulation and enforcement are parallel, not sequential. The PCAC voted in July 2026 to recommend adding six peptides, including BPC-157, to the Section 503A Bulk Drugs List — a non-binding step that does not affect the RUO products at issue. Whether FDA enforcement will extend to those six peptides remains unsettled; FDA's recent actions illustrate a shifting enforcement landscape rather than a settled focus on any single peptide category.

Until the FDA converts advisory committee recommendations into rulemaking — a process that typically takes many months — the legal status of the peptides in question remains unchanged, and enforcement can proceed in parallel with policy reform.